Drug Trial Radar · NCT05064345
A Study to Evaluate HB0034 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Sep 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Dec 3, 2021
Primary completion
Sep 1, 2022
Study completion Sep 1, 2022
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose.
Conditions
- Healthy
Interventions
HB0034Drug
Recombinant Humanized Anti-IL-36R Monoclonal antibody
PlaceboDrug
Palcebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with drug related adverse events (AEs)Time frame: up to 2000 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New zealand Clinical Research
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.